Bumetanide and stx64 share 14 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.424 means 42% of the combined target set is bound by both compounds. The IDF-weighted score of 0.373 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Bumetanide and stx64 have in common?
Bumetanide and stx64 share 14 molecular targets with a Jaccard similarity of 42%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Bumetanide and stx64 be combined?
Bumetanide and stx64 share 14 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Bumetanide or stx64?
Both Bumetanide and stx64 have substantial PubMed research. View their individual profiles for full evidence scores.